CYP19A1 and breast cancer: In breast cancer, the therapeutic potential of MM-121 is being tested in patients with estrogen receptor- and/or progesterone receptor-positive and erbB2-negative breast cancers in combination with the aromatase inhibitor exemestane, and in patients with triple-negative or erbB2-negative breast cancers in combination with paclitaxel.